← Back to Analyst Consensus 
BVS Buy
Bioventus Inc.
Current Price —
Implied Upside —
Analysts 9
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Aug 17, 2026 | Cantor Fitzgerald | reiterate | Overweight → Overweight | — | 50% |
| Jun 30, 2026 | Barrington Research | maintain | Outperform → Outperform | — | 55% |
| Jun 16, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| May 22, 2026 | Barrington Research | maintain | Outperform → Outperform | — | 55% |
| Mar 6, 2026 | Barrington Research | maintain | Outperform → Outperform | — | 55% |
| Mar 6, 2026 | Craig-Hallum | maintain | Buy → Buy | — | 54% |
| Feb 9, 2026 | Barrington Research | initiate | — → Outperform | $13 | 55% |
| Jul 7, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $12 | 50% |
| Mar 17, 2025 | Canaccord Genuity | maintain | Buy → Buy | $15 | 48% |
| Dec 17, 2024 | JP Morgan | upgrade | Underweight → Neutral | $13 | 55% |
| Nov 6, 2024 | Canaccord Genuity | maintain | Buy → Buy | $15 | 48% |
| Sep 27, 2024 | Craig-Hallum | maintain | Buy → Buy | $17 | 54% |
| Aug 13, 2024 | Canaccord Genuity | maintain | Buy → Buy | $12 | 48% |
| Aug 7, 2024 | Craig-Hallum | maintain | Buy → Buy | $12 | 54% |
| May 8, 2024 | Canaccord Genuity | maintain | Buy → Buy | $8 | 48% |
| Mar 13, 2024 | Craig-Hallum | maintain | Buy → Buy | $9 | 54% |
| Dec 7, 2023 | Canaccord Genuity | upgrade | Hold → Buy | $7 | 48% |
| Apr 3, 2023 | Craig-Hallum | maintain | — → Hold | $5 | 54% |
| Nov 30, 2022 | Goldman Sachs | maintain | — → Neutral | $2.5 | 54% |
| Nov 22, 2022 | Craig-Hallum | downgrade | Buy → Hold | $0 | 54% |
| Nov 10, 2022 | Morgan Stanley | maintain | — → Overweight | $5 | 54% |
| Nov 9, 2022 | Canaccord Genuity | downgrade | Buy → Hold | $0 | 48% |
| Nov 9, 2022 | JP Morgan | downgrade | Overweight → Underweight | $0 | 55% |
| Oct 11, 2022 | Morgan Stanley | maintain | — → Overweight | $11 | 54% |
| Sep 7, 2022 | Goldman Sachs | maintain | — → Neutral | $13 | 54% |
| Aug 12, 2022 | Morgan Stanley | maintain | — → Overweight | $12 | 54% |
| May 12, 2022 | Morgan Stanley | maintain | — → Overweight | $11 | 54% |
| Mar 21, 2022 | Goldman Sachs | maintain | — → Neutral | $17 | 54% |
| Mar 15, 2022 | Craig-Hallum | initiate | — → Buy | $30 | 54% |
| Mar 11, 2022 | Morgan Stanley | maintain | — → Overweight | $18 | 54% |
| Jul 1, 2021 | Goldman Sachs | downgrade | Buy → Neutral | $19 | 54% |
| Apr 19, 2021 | Morgan Stanley | maintain | — → Overweight | $19 | 54% |
| Mar 8, 2021 | Canaccord Genuity | initiate | — → Buy | $23 | 48% |
| Mar 8, 2021 | Morgan Stanley | initiate | — → Overweight | $18 | 54% |
| Mar 8, 2021 | JP Morgan | initiate | — → Overweight | $17 | 55% |
| Mar 8, 2021 | Goldman Sachs | initiate | — → Buy | $19 | 54% |
Price Target Trend
May 9, 2026 Oct 27, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days